Real Time Touch

new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)

Real Time Touch

Glaxo Group Limited patents

Recent patent applications related to Glaxo Group Limited. Glaxo Group Limited is listed as an Agent/Assignee. Note: Glaxo Group Limited may have other listings under different names/spellings. We're not affiliated with Glaxo Group Limited, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Glaxo Group Limited-related inventors

2-(azaindol-2-yl) benzimidazoles as pad4 inhibitors

. . Compounds of formula (i) wherein; r1 is hydrogen or c1-6alkyl; r2 is hydrogen, c1-6alkyl, perhalomethylc0-5alkyl-o—, or c1-6alkoxy; r3 is hydrogen, c1-6alkyl, or c1-6alkoxyc1-6alkyl; r4 is hydrogen, c1-6alkyl, perhalomethylc1-6alkyl; or unsubstituted c3-6cycloalkylc1-6alkyl; a is c—r5 or n; b is c—r6 or n; d is c—r7 or n; with the proviso that at least one of a, b, and d, is n; r5 is hydrogen or c1-6alkyl; r6 is hydrogen or c1-6alkyl; r7 is hydrogen, c1-6alkyl, c1-6alkoxy, or hydroxy; r8 is hydrogen or c1-6alkyl, with the proviso that one of r4 and r8 is hydrogen; r9 is hydrogen or hydroxy; r1o is hydrogen or c1-6alkyl; and salts thereof are pad4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.. . ... Glaxo Group Limited

Antigen binding proteins

The present invention concerns antigen binding proteins and fragments thereof which specifically bind b cell maturation antigen (bcma), particularly human bcma (hbcma) and which inhibit the binding of baff and april to the bcma receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.. ... Glaxo Group Limited

Method of producing a recombinant protein

The present invention relates to a method of producing a recombinant protein in a host cell comprising adding polyethyleneimine (pei) during cell culture. Addition of pei to the cell culture as a fermentation enhancer can result in reducing the viscosity of the cell culture, and/or increasing the extracellular concentration of the recombinant protein, and/or reducing the duration of cell culture to the point of harvest or protein recovery.. ... Glaxo Group Limited

Methods for selecting protease resistant polypeptides

The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, incubating the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. ... Glaxo Group Limited

Ligands that bind tgf-beta receptor ii

The disclosure provides an anti-tgfbetarii immunoglobulin single variable domain. Suitably, an anti-tgfbetarii immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of seq id no:1-28 having up to 5 amino acid substitutions, deletions or additions. ... Glaxo Group Limited

Novel composition

The invention relates to non-aqueous dentrfrice compositions comprising a surfactant system. The surfactant system consists of a combination of surfactants i.e. ... Glaxo Group Limited

Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist

Combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.. . ... Glaxo Group Limited

Positive allosteric modulators of human melanocortin-4 receptor

Disclosed herein are positive allosteric modulators of melanocortin receptor and methods of using such modulators.. . ... Glaxo Group Limited

Process for separation of oligonucleotide of interest from a mixture

A method for separation of an oligonucleotide from a mixture using a biphasic mobile phase/stationary phase liquid-liquid chromatography system. A first mobile phase contains the oligonucleotide and the stationary phase contains an exchanger substance that removably binds to the target oligonucleotide. ... Glaxo Group Limited

Medicament dispenser

An inhalation device having at least one elongate medicament carrier including, but not limited to, a pair of sheets sealed together and a plurality of medicament powder doses positioned at spaced-apart locations between said sealed sheets, an outlet for a user to inhale from, and a mechanism for stepwise advancement of the at least one elongate medicament carrier.. . ... Glaxo Group Limited

Novel milk beverage composition comprising creatine

. . Ready to drink milk beverage compositions are described comprising creatine and an added protein such as whey protein, which have good creatine shelf life at ambient temperatures.. . ... Glaxo Group Limited

Antigen binding proteins to oncostatin m (osm)

The present invention concerns antigen binding proteins and fragments thereof which specifically bind oncostatin m (osm), particularly human osm (hosm) and which inhibit the binding of osm to the gp130 receptor but does not directly interact with site ii residues. The invention also concerns a method of humanising antibodies. ... Glaxo Group Limited

Child-proof package

. . A package which can be torn open by a user, comprising a polymer film material having a preferential tearing direction and defining a cavity for a product, wherein the polymer film material incorporates a bias facilitating tearing along a tear line oriented in a direction other than its preferential tearing direction and a tear initiation location which facilitates tearing of the polymer film material in its preferential tearing direction to open the package, the tear line being adjacent to a tear initiation location. The polymer film material having a preferential tearing direction provides resistance against a child tearing open the package.. ... Glaxo Group Limited

Novel compounds

The present invention is directed to novel retinoid-related orphan receptor gamma (rorγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by rorγ.. . ... Glaxo Group Limited

02/02/17 / #20170029497


The present invention discloses humanised anti-il-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.. ... Glaxo Group Limited

02/02/17 / #20170029494

Antigen binding constructs

The present invention is directed to antigen binding constructs comprising one or two epitope binding domains separated by a single chain fc region of an antibody, wherein each epitope binding domain in capable of binding to vegf, to dimers comprising two antigen binding constructs of the invention, pharmaceutical compositions comprising said dimers and their use in the treatment of diseases associated with vegf signalling, such as diabetic macular edema (dme), wet age-related macular degeneration (wet amd), diabetic retinopathy, retinal vein occlusion (rvo), and corneal neovascularisation, and polynucleotide sequences encoding said antigen binding constructs.. . ... Glaxo Group Limited

01/19/17 / #20170015656

Novel compounds

The invention is directed to certain novel compounds. Specifically, crystalline forms of n-[5-[4-(5-{[(2r,6s)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1h-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide and crystalline 6-(1h-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1h-indazole, along with salts thereof.. ... Glaxo Group Limited

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009


This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. is not affiliated or associated with Glaxo Group Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Glaxo Group Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by